Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

High-performance biomechanical model of combined immunotherapy and anti-angiogenic cancer treatment

Descrizione del progetto

La strada vascolare per un’immunoterapia efficace

La crescita tumorale e l’erogazione del trattamento dipendono fortemente dalla vascolarizzazione del tumore stesso. Le cellule tumorali producono molecole che incoraggiano l’angiogenesi, supportando la loro rapida crescita e la transizione da tumori benigni a maligni. Queste molecole inoltre rendono i vasi sanguigni permeabili e porosi. La porosità aiuta le cellule tumorali a penetrare nel flusso ematico e a diffondersi, compromettendo al contempo la somministrazione di chemio- e immuno-terapie. Alcuni scienziati finanziati dall’UE stanno sviluppando modelli computazionali di microambienti tumorali e riparazione di anomalie vascolari per comprendere meglio gli effetti della perfusione vascolare ottimizzata sulle immunoterapie promettenti. Le previsioni saranno testate in modelli sperimentali.

Obiettivo

Inefficient delivery of cellular and molecular medicines to solid tumors can reduce dramatically the efficacy of treatment and affect negatively patient’s survival. This explains in large part why standard chemo- and immune-therapies often fail to treat specific cancer types, even though these therapies are potent enough to eradicate cancer cells. Abnormalities in the structure of the tumor vasculature hinder tumor perfusion and as a result the systemic delivery of the medicines. In many tumor types, blood vessels are hyper-permeable, leaving large interendothelial openings, which causes fluid loss from the vascular to the interstitial tumor space. Vessel hyper-permeability can reduce tumor blood flow, rendering tumors hypo-perfused and hypoxic. Impaired blood supply and hypoxia help cancer cells evade the immune system and increase their invasive and metastatic potential. Normalization of the tumor vasculature is a clinical strategy to repair vascular abnormalities in order to improve perfusion, oxygenation and delivery of medicines. Immunotherapy is gaining interest as an effective therapeutic approach against cancer, but only a subset of patients receiving immunotherapy exhibit sustained tumor shrinkage. Here, we hypothesize that vascular normalization can improve immunotherapy. The objective of the proposed research is the optimal design of the combined immunotherapy and vascular normalization therapeutic approach. To this end, a numerical and experimental study is proposed to model and experimentally validate the vascular normalization procedure, focusing on its combined effects with immunotherapeutic drugs. The proposed research/training will complement the Applicant’s skills in high-performance computing, advanced optimization algorithms and artificial neural networks with the Host’s expertise in tumor microenvironment and cancer drug delivery to enhance his professional maturity and promote international collaborations.

Invito a presentare proposte

H2020-WF-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-WF-01-2018

Meccanismo di finanziamento

MSCA-IF-EF-ST - Standard EF

Coordinatore

UNIVERSITY OF CYPRUS
Contribution nette de l'UE
€ 145 941,12
Indirizzo
AVENUE PANEPISTIMIOU 2109 AGLANTZI
1678 Nicosia
Cipro

Mostra sulla mappa

Regione
Κύπρος Κύπρος Κύπρος
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 145 941,12